agilon health, inc. (AGL) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
agilon health, inc. (AGL)
A forensic read on agilon health, inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-7.3
Altman Z-score
Clean
Earnings quality
4
Forensic signals
-138.6%
ROE
$2.0B
Market cap
Agilon health, inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -7.3, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-907%Return on invested capital.Return on invested capital is -907% and slipping from -12% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
stoppedShareholder returns — halted.Capital returns have STOPPED — $200M of buybacks + dividends in FY2023, but ~$0 in FY2025. A halt usually means the company is conserving cash; understand why before reading it as neutral.
+0.5%/yrShare-count dilution.Diluted share count changed +1% over the last 3 years to FY2025 (+0.5%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
$24MGoodwill impairments.Took $24M of goodwill writedowns across 1 year(s) (FY2025 ($24M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-6.6%
Debt / Equity0.28x
Free Cash Flow$-119.0M
Latest Revenue$5.93B
Return on Equity-308.8%
Revenue Growth YoY-2.1%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on agilon health, inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about AGL's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown